------------------------------------------------------------

** New Report on HIV Prevention Research Funding
------------------------------------------------------------
July 17, 2015

Dear Advocate,

We are pleased to announce the release of HIV Prevention Research & Development Funding Trends 2000–2014: Investing in innovation in an evolving global health and development landscape ([link removed]) .

This is the eleventh annual report on HIV prevention research funding prepared by the HIV Vaccines & Microbicides Resource Tracking Working Group (RTWG) ([link removed]) , led by AVAC, in partnership with the International AIDS Vaccine Initiative ([link removed]) and UNAIDS ([link removed]) . Report graphics and presentations are available at www.hivresourcetracking.org ([link removed]) .

The report provides detailed information on funding for research and development (R&D) on HIV prevention options—preventive AIDS vaccines, microbicides, pre-exposure prophylaxis (PrEP), use of ART in people living with HIV, use of ART to prevent infections in infants born to women living with HIV, voluntary medical male circumcision and female condoms. In addition to funding information for R&D on the options above, the report also provides an update on investment in HIV cure, therapeutic vaccines, HSV-2 vaccines and multipurpose prevention technology research.

Top-line findings include:
* In 2014 funders reported investing a total of US$1.25 billion in R&D for HIV prevention—a small decrease over 2013 funding levels which totaled US$1.26 billion. This flat-lining of funding reflects a decline in purchasing power, given inflation.
* The United States remained the largest public sector funder of HIV prevention research, spending a total of US$868 million in 2014—66 percent of the total investment in HIV prevention R&D. Combined, the US public sector and the Bill & Melinda Gates Foundation accounted for 83 percent of all R&D funding. The number of philanthropic funders engaged in HIV prevention research continued a steadily decline since 2010.
* In 2014, there were over one million participants in HIV prevention research trials, primarily based in sites with high HIV burden in South Africa, Uganda and the US. Eighty-six percent of volunteers were in sub-Saharan Africa.


The report is being released at the 8th IAS Conference on HIV Pathogenesis, Treatment and Prevention ([link removed]) which begins this weekend in Vancouver, It provides background information for anyone advocating for biomedical HIV prevention research.

Visit the Working Group's website at www.hivresourcetracking.org ([link removed]) to downloadHIV Prevention Research & Development Funding Trends 2000–2014: Investing in innovation in an evolving global health and development landscape ([link removed]) and to view additional Working Group reports ([link removed]) , as well as graphics ([link removed]) and PowerPoint slides ([link removed]) .

As always, please feel free to contact us (mailto:[email protected]) with any questions or comments.

Best,
AVAC

============================================================
Forward This Issue Do you know someone who might be interested in receiving this newsletter?
** Forward > ([link removed])


Contact Us T: +1 212 796 6423
E: ** [email protected] (mailto:[email protected])
W: ** www.avac.org ([link removed])
** ([link removed])
** ([link removed])
** ([link removed])
==============================================

Unsubscribe [email protected] from this list:
[link removed]